首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL18BP |
| Uniprot No | O95998 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-194aa |
| 氨基酸序列 | ADPTPVSQTTTAATASVRSTKDPCPSQPPVFPAAKQCPALEVTWPEVEVP LNGTLSLSCVACSRFPNFSILYWLGNGSFIEHLPGRLWEGSTSRERGSTG TQLCKALVLEQLTPALHSTNFSCVLVDPEQVVQRHVVLAQLWAGLRATLP PTQEALPSSHSSPQQQGLEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK HHHHHH |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与IL-18BP重组蛋白相关的代表性文献及其摘要概括：
1. **文献名称**：*Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response*
**作者**：Novick D. 等
**摘要**：该研究首次克隆并表征了重组IL-18BP蛋白，证实其通过高亲和力结合IL-18.抑制IL-18介导的IFN-γ产生，揭示了其在调控Th1免疫反应中的潜在应用价值。
2. **文献名称**：*Recombinant human IL-18 binding protein inhibits endotoxin-induced inflammation in vitro and in vivo*
**作者**：Kim S.H. 等
**摘要**：研究通过体外细胞实验和小鼠脓毒症模型，证明重组IL-18BP可显著降低LPS诱导的炎症因子(如TNF-α、IL-6)水平，改善器官损伤，提示其作为抗炎治疗药物的潜力。
3. **文献名称**：*IL-18 neutralization by recombinant IL-18 binding protein in collagen-induced arthritis*
**作者**：Platzer C. 等
**摘要**：在胶原诱导的关节炎模型中，重组IL-18BP通过阻断IL-18信号通路，减轻关节炎症和骨质破坏，验证了其在自身免疫性疾病中的治疗作用机制。
4. **文献名称**：*Structural and functional analysis of recombinant human IL-18BP*
**作者**：Kato Z. 等
**摘要**：通过X射线晶体学解析IL-18BP与IL-18的复合物结构，阐明其抑制机制，并优化重组蛋白的稳定性，为药物开发提供结构基础。
以上文献覆盖了重组IL-18BP的发现、机制研究、疾病模型验证及结构优化等关键方向。
Interleukin-18 binding protein (IL-18BP) is a naturally occurring soluble protein that acts as a critical regulator of IL-18. a pro-inflammatory cytokine involved in innate and adaptive immune responses. Discovered in the late 1990s, IL-18BP belongs to the IL-1 cytokine family and functions as a decoy receptor by binding to IL-18 with high affinity, thereby neutralizing its activity. This interaction prevents IL-18 from engaging its cell surface receptor (IL-18R), which is essential for initiating downstream inflammatory signaling pathways, including NF-κB activation and interferon-gamma (IFN-γ) production.
Recombinant IL-18BP (rIL-18BP) is produced through genetic engineering, typically using mammalian or bacterial expression systems. Its therapeutic potential stems from its ability to modulate excessive IL-18-driven inflammation, which is implicated in autoimmune diseases (e.g., rheumatoid arthritis, macrophage activation syndrome), chronic inflammatory disorders, and certain infections. Notably, IL-18 overexpression correlates with pathological conditions like sepsis, Crohn’s disease, and cytokine release syndrome. rIL-18BP has shown efficacy in preclinical models by attenuating inflammation and restoring immune homeostasis.
Human IL-18BP exists in four isoforms (a-d), with isoform a being the most studied and clinically relevant due to its potent IL-18-neutralizing capacity. Research highlights its dual role: while suppressing harmful inflammation, it may also fine-tune immune surveillance. Current clinical investigations focus on optimizing rIL-18BP for therapeutic use, balancing efficacy with safety in conditions where IL-18 dysregulation drives disease progression. Its development represents a targeted approach to cytokine-specific immunomodulation, offering promise for precision medicine in inflammation-related pathologies.
×
